Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022
Eagle Pharmaceuticals, Inc. (EGRX) will release its 2022 third quarter financial results on November 7, 2022, before market opening. A conference call will be hosted by CEO Scott Tarriff and CFO Brian Cahill at 8:30 a.m. ET, with a toll-free number for U.S. participants and an international line provided. The call will be available for replay for two weeks, while the webcast can be accessed for 30 days. Eagle specializes in developing innovative medicines, with products like PEMFEXY®, RYANODEX®, and others aimed at addressing critical therapeutic areas.
- Eagle is a fully integrated pharmaceutical company with strong R&D and commercial expertise.
- The upcoming financial results announcement may provide insights into the company's performance and future outlook.
- None.
WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens.
Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Date | Monday, November 7, 2022 | |
| Time | 8:30 a.m. ET | |
| Toll free (U.S.) | 800-343-4849 | |
| International | 785-424-1699 | |
| Webcast (live and replay) | www.eagleus.com, under the “Investor Relations” section |
A replay of the conference call will be available for two weeks after the call's completion by dialing 800-934-4548 (U.S.) or 402-220-1175 (International) and entering conference call ID EGRXQ322. The webcast will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin, PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly-owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.
Contact:
Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Eagle Pharmaceuticals release its third-quarter financial results for 2022?
What time is the conference call for Eagle Pharmaceuticals' Q3 2022 results?
How can I access the replay of Eagle Pharmaceuticals' conference call?
What products does Eagle Pharmaceuticals offer?
